Status:

COMPLETED

Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment

Lead Sponsor:

Novartis

Conditions:

Traumatic Brain Injury

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with traumatic brain injury and cognitive impairment.

Eligibility Criteria

Inclusion

  • Traumatic brain injury confirmed by available brain imaging (CT or MRI) and be at least 52 weeks post injury
  • Neuropsychologic disturbances indicated by: impaired memory (reduction of below 1 standard deviation (SD) of the mean on the California Verbal Learning Test (CVLT) and impaired executive function (reduction of below 1 standard deviation (SD) of the mean on the Verbal Memory Learning Test (VLMT) and Tower of London Test (ToL) and impaired attention (reduction of below 1 standard deviation (SD) of the mean on the Test Battery for Attentional Performance (TAP)
  • Be required to have had sufficient education to read, write, and effectively communicate
  • Be cooperative, able to ingest oral medication, and able to complete all aspects of the study and capable of doing so, either alone or with the aid of a responsible caregiver according to the investigator's judgement

Exclusion

  • A current diagnosis of cerebrovascular disease, any primary neurodegenerative disorder, or any other causes of neuropsychologic disturbances
  • A current diagnosis of active, uncontrolled seizure disorder or major depression, or any other diagnosis that may interfere with the patient's response to study medication
  • An advanced, severe or unstable disease of any type that may interfere with efficacy evaluations
  • Female patients with child-bearing potential who are breast-feeding, pregnant or not practicing non-hormonal contraception
  • Other protocol-defined inclusion/exclusion criteria may apply.

Key Trial Info

Start Date :

November 1 2002

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2005

Estimated Enrollment :

67 Patients enrolled

Trial Details

Trial ID

NCT00171795

Start Date

November 1 2002

End Date

May 1 2005

Last Update

November 23 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.